[go: up one dir, main page]

MA54673A1 - Stéroïdes et leurs conjugués-anticorps - Google Patents

Stéroïdes et leurs conjugués-anticorps

Info

Publication number
MA54673A1
MA54673A1 MA54673A MA54673A MA54673A1 MA 54673 A1 MA54673 A1 MA 54673A1 MA 54673 A MA54673 A MA 54673A MA 54673 A MA54673 A MA 54673A MA 54673 A1 MA54673 A1 MA 54673A1
Authority
MA
Morocco
Prior art keywords
conjugates
steroids
antibody
glucocorticoids
steroid
Prior art date
Application number
MA54673A
Other languages
English (en)
Inventor
Amy Han
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA54673A1 publication Critical patent/MA54673A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des conjugués de stéroïdes- protéines qui sont utiles, par exemple, pour l'administration spécifique à une cible de glucocorticoïdes (gc) à des cellules.
MA54673A 2018-01-08 2019-01-08 Stéroïdes et leurs conjugués-anticorps MA54673A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862614905P 2018-01-08 2018-01-08
PCT/US2019/012786 WO2019136487A2 (fr) 2018-01-08 2019-01-08 Stéroïdes et leurs conjugués-anticorps

Publications (1)

Publication Number Publication Date
MA54673A1 true MA54673A1 (fr) 2022-08-31

Family

ID=65411936

Family Applications (2)

Application Number Title Priority Date Filing Date
MA54673A MA54673A1 (fr) 2018-01-08 2019-01-08 Stéroïdes et leurs conjugués-anticorps
MA50259A MA50259A1 (fr) 2018-01-08 2019-01-08 Stéroïdes et leurs conjugués-anticorps

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA50259A MA50259A1 (fr) 2018-01-08 2019-01-08 Stéroïdes et leurs conjugués-anticorps

Country Status (17)

Country Link
US (2) US12070506B2 (fr)
EP (1) EP3737420A2 (fr)
JP (2) JP7366028B2 (fr)
KR (1) KR20200108002A (fr)
CN (2) CN118955604A (fr)
AU (1) AU2019205542A1 (fr)
BR (1) BR112020013492A2 (fr)
CA (1) CA3086926A1 (fr)
CL (1) CL2020001813A1 (fr)
CO (1) CO2020009644A2 (fr)
EA (1) EA202091672A1 (fr)
IL (1) IL275757A (fr)
MA (2) MA54673A1 (fr)
MX (1) MX2020006994A (fr)
PH (1) PH12020551044A1 (fr)
SG (1) SG11202006510XA (fr)
WO (1) WO2019136487A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019005330A (es) 2016-11-08 2019-09-11 Regeneron Pharma Esteroides y conjugados de proteinas de los mismos.
MX2019013690A (es) 2017-05-18 2020-01-27 Regeneron Pharma Conjugados de farmaco-proteina con ciclodextrina.
KR20200085807A (ko) 2017-11-07 2020-07-15 리제너론 파마슈티칼스 인코포레이티드 항체 약물 접합제용 친수성 링커
MA54673A1 (fr) 2018-01-08 2022-08-31 Regeneron Pharma Stéroïdes et leurs conjugués-anticorps
CA3098453A1 (fr) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anticorps anti-msr1 et leurs procedes d'utilisation
KR20210114008A (ko) * 2019-01-08 2021-09-17 리제너론 파마슈티칼스 인코포레이티드 흔적이 없는 링커 및 이의 단백질-접합체
IT202000006442A1 (it) * 2020-03-27 2021-09-27 Genetic S P A Budesonide 21-phosphate salts and pharmaceutical compositions containing the same
JP2023072104A (ja) * 2020-04-10 2023-05-24 小野薬品工業株式会社 抗体薬物複合体
CN116096374A (zh) * 2020-08-10 2023-05-09 P.I.F.企业家有限公司 巨噬细胞靶向的药物缀合物
KR20230107261A (ko) 2020-11-10 2023-07-14 리제너론 파마슈티칼스 인코포레이티드 셀레늄 항체 접합물
WO2022135332A1 (fr) * 2020-12-21 2022-06-30 映恩生物制药（苏州）有限公司 Conjugué de stéroïdes
EP4289857A1 (fr) * 2021-02-04 2023-12-13 Shanghai Senhui Medicine Co., Ltd. Conjugué médicamenteux d'agoniste du récepteur de glucocorticoïde et son utilisation en médecine
WO2022171101A1 (fr) * 2021-02-10 2022-08-18 映恩生物制药（苏州）有限公司 Conjugué de stéroïdes
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
NL2029599B1 (en) * 2021-11-02 2023-06-01 Univ Leiden Glycosylated Prodrugs
WO2023143351A1 (fr) 2022-01-29 2023-08-03 上海盛迪医药有限公司 Conjugué de médicament de glucocorticoïde
US20240067640A1 (en) 2022-03-11 2024-02-29 Firefly Bio, Inc. Phenyl maleimide linker agents
CN115785188B (zh) * 2022-12-20 2024-06-07 湖南科益新生物医药有限公司 一种布地奈德的制备方法

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2920999A (en) 1957-06-07 1960-01-12 Pfizer & Co C 21-nitrogen derivatives of corticosteroids
DE1165595B (de) * 1958-03-04 1964-03-19 Olin Mathieson Verfahren zur Herstellung von Triamcinolonacetonid-21-hemisuccinat und dessen Salzen
GB889766A (en) * 1958-03-04 1962-02-21 Olin Mathieson Improvements in steroids and the synthesis thereof
US3197469A (en) 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3007923A (en) 1959-01-22 1961-11-07 Lab Francais Chimiotherapie Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
GB898291A (en) 1959-03-18 1962-06-06 Upjohn Co Improvements in or relating to steroids and the manufacture thereof
US3033873A (en) 1960-05-11 1962-05-08 Pfizer & Co C 21-aminomethyl-pregnenes
US3033874A (en) 1960-05-11 1962-05-08 Pfizer & Co C 17beta-propenoyl steroids and process for preparing same
US3020275A (en) 1960-06-07 1962-02-06 American Cyanamid Co 21-nitrogen substituted steroids of the pregnane series and methods of preparing the same
DE1169444B (de) 1961-02-22 1964-05-06 Schering Ag Verfahren zur Herstellung von ?-16ª‡-Methylsteroiden
US3047468A (en) 1961-06-06 1962-07-31 American Cyanamid Co Method of preparing delta1, 4-3-keto steroids of the pregnane series
US3383394A (en) 1965-08-30 1968-05-14 Schering Corp Novel 17-acylating process and products thereof
US3798216A (en) 1969-03-07 1974-03-19 Fabrication Des Antibiotique S 9-fluoro-11beta,21-dihydroxy-16alpha,17-(2-propenylidenedioxy)-pregna-1,4-diene-3,20-dione and derivatives thereof
NL7001308A (fr) * 1969-03-07 1970-09-09
DE2047105C3 (de) 1970-09-18 1979-02-15 Schering Ag, 1000 Berlin Und 4619 Bergkamen 17-Chlorsteroide und Verfahren zu ihrer Herstellung
IT1057859B (it) 1972-04-28 1982-03-30 Sigma Tao Ind Farmaceutiche Sp Perivato del triamoinolone
SE378110B (fr) 1972-05-19 1975-08-18 Bofors Ab
SE378109B (fr) 1972-05-19 1975-08-18 Bofors Ab
US4076737A (en) 1975-02-20 1978-02-28 Ciba-Geigy Corporation Aldehydes of the pregnane series and derivatives thereof
IL73337A (en) 1984-10-28 1988-09-30 Yissum Res Dev Co Antitumor steroid-platinum complexes and method for the preparation thereof
SE8604059D0 (sv) 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5116829A (en) 1990-04-23 1992-05-26 Kao Corporation Steroid compounds
US5183815A (en) 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
DK0678097T3 (da) 1993-01-08 2000-02-07 Astra Ab Hidtil ukendte colon- eller ileumspecifikke steroidderivater
DE4311987A1 (de) * 1993-04-07 1994-10-13 Schering Ag Neue Glucocorticoide
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US5837698A (en) 1996-05-02 1998-11-17 G. D. Searle & Co. Steroid nitrite and nitrate ester derivatives useful as anti-inflammatory drugs
AU3703900A (en) 1999-02-24 2000-09-14 Nitromed, Inc. Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
SE0101220D0 (sv) 2001-04-04 2001-04-04 Astrazeneca Ab New use
US6908934B2 (en) 2001-06-11 2005-06-21 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
ITMI20020148A1 (it) 2002-01-29 2003-07-29 Nicox Sa Nuovi corticosteroidi
US20050009798A1 (en) 2002-02-20 2005-01-13 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
GR1004274B (el) * 2002-07-16 2003-06-23 Medexis ���� Συμπλοκα στεροειδων ορμονων με πρωτεινες: νεες ουσιες για την ειδικη ανιχνευση και καταστροφη καρκινικων κυτταρων προερχομενων απο στερεους ογκους και αιματολογικες κακοηθειες
WO2004010957A2 (fr) 2002-07-31 2004-02-05 Seattle Genetics, Inc. Conjugues de medicaments et leur utilisation dans le traitement du cancer, d'une maladie auto-immune ou d'une maladie infectieuse
US20040157810A1 (en) 2002-08-23 2004-08-12 Teicher Martin H. Corticosteroid conjugates and uses thereof
MX367615B (es) 2002-09-06 2019-08-28 Cerulean Pharma Inc Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos.
CN1414008A (zh) 2002-10-17 2003-04-30 南开大学 含氮甾体化合物及其制备方法
US7015349B2 (en) 2003-03-26 2006-03-21 The Gillette Company Reduction of hair growth
AU2004316290C1 (en) 2003-11-06 2012-02-02 Seagen Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2005063777A1 (fr) 2003-12-23 2005-07-14 Corus Pharma Promedicaments de benzylphosphate et de benzylphosphate substitue utilises dans le traitement d'une inflammation pulmonaire
WO2005079523A2 (fr) 2004-02-18 2005-09-01 University Of Georgia Research Foundation, Inc. Nouveaux polypeptides antimicrobiens derives de teleosteens
US20050192257A1 (en) 2004-02-26 2005-09-01 Peyman Gholam A. Predictors for patients at risk for glaucoma from steroid therapy
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
EP2286844A3 (fr) 2004-06-01 2012-08-22 Genentech, Inc. Conjugués anticorps-médicament et procédés
EP1602931A1 (fr) 2004-06-03 2005-12-07 Universiteit Leiden Antagoniste du SR-A
US7541330B2 (en) 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
EP1625854B1 (fr) 2004-08-09 2008-10-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Conjugés d'albumine contenant un lien glucuronique
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
CA2587589A1 (fr) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Anticorps et immunoconjugues mis au point
WO2006135371A1 (fr) 2005-06-09 2006-12-21 Kosan Biosciences Incorporated Conjugués à effets adverses systémiques réduits
BRPI0611567A2 (pt) 2005-06-14 2016-11-16 Gilead Sciences Inc composto e/ou sais farmaceuticamente aceitáveis dos mesmos, processo para síntese dos compostos, e formulação aerossol, e, uso de pelo menos uma pró-droga mútua de fenilfosfato
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2008127347A1 (fr) 2006-07-21 2008-10-23 Diadexus, Inc. Compositions d'anticorps anti-pro 115 et procédés d'utilisation
EP2073820A4 (fr) 2006-09-15 2014-07-16 Belrose Pharma Inc Promédicaments polymères ciblés contenant des segments de liaison multifonctionnels
AU2008213046B2 (en) 2007-02-05 2013-02-14 Nicox S.A. Nitric oxide releasing steroids
WO2008122039A2 (fr) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molécules d'anticorps hybrides médiées par la sélénocystéine
EP3561513A1 (fr) 2007-05-23 2019-10-30 Ventana Medical Systems, Inc. Supports polymères pour immunohistochimie et hybridation in situ
CA2690943A1 (fr) * 2007-06-25 2008-12-31 Endocyte, Inc. Conjugues contenant des lieurs espaceurs hydrophiles
EP2170054A4 (fr) 2007-06-28 2012-08-08 Capsutech Ltd Ciblage de conjugues renfermant des agents actifs encapsules dans des polymeres contenant de la cyclodextrine
CN101397328A (zh) * 2007-09-27 2009-04-01 天津药业研究院有限公司 一氧化氮供体型糖皮质激素
PT2214646T (pt) * 2007-10-05 2021-09-29 Univ Wayne State Dendrímeros para libertação sustentada de compostos
PE20091215A1 (es) 2007-12-21 2009-08-14 Schering Corp Tioeteres c-21 como agonistas del receptor de glucocorticoides
CL2008003803A1 (es) 2007-12-21 2010-02-19 Schering Corp Compuestos derivados de esteroides c20-21 sustituidos, agonistas del receptor de glucocorticoide; composicion farmaceutica que comprende a dicho compuesto; y uso para tratar o prevenir una enfermedad o afeccion inmune, autoinmune o inflamatoria, tales como colitis inflamatoria y artritis reumatoide.
WO2009134976A1 (fr) 2008-04-30 2009-11-05 Immunogen, Inc Conjugués puissants et coupleurs hydrophiles
TW201010707A (en) 2008-06-10 2010-03-16 Gilead Sciences Inc Corticosteroid linked beta-agonist compounds for use in therapy
PL2326349T3 (pl) 2008-07-21 2015-08-31 Polytherics Ltd Nowe reagenty i sposób sprzęgania cząsteczek biologicznych
CA2731617A1 (fr) 2008-07-22 2010-01-28 Maria Joao Saraiva Sequences d'acides amines dirigees contre des recepteurs de desactiveurs multicibles et polypeptides
KR101000067B1 (ko) 2008-12-30 2010-12-10 엘지전자 주식회사 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법
AU2010221972B2 (en) 2009-03-09 2012-07-05 Mikasa Seiyaku Co., Ltd. Steroid compound
WO2010126953A1 (fr) 2009-04-29 2010-11-04 Gilead Sciences, Inc. Composés bêta-agonistes liés à des corticostéroïdes pour une utilisation en thérapie
WO2010132743A1 (fr) * 2009-05-15 2010-11-18 Gilead Sciences, Inc. Composés de β-agonistes et de corticostéroïdes destinés à être utilisés en thérapie
DK2889624T3 (en) 2009-08-10 2018-12-10 Ucl Business Plc Reversible covalent bonding of functional molecules
WO2011020107A2 (fr) 2009-08-14 2011-02-17 Georgetown University Compositions et méthodes de dépistage et de traitement du cancer du sein
GB0917044D0 (en) 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
GB0917054D0 (en) 2009-09-29 2009-11-11 Cytoguide As Agents, uses and methods
WO2011081937A1 (fr) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Composés de type corticostéroïde-bêta-agoniste-antagoniste muscarinique pour applications thérapeutiques
WO2011090940A1 (fr) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Polymères à base de cyclodextrine pour administration thérapeutique
WO2011103389A1 (fr) 2010-02-19 2011-08-25 Cornell University Procédé pour traiter des maladies démyélinisantes auto-immunes et d'autres maladies auto-immunes ou inflammatoires
CA2793890C (fr) 2010-04-15 2017-08-15 Spirogen Developments Sarl Pyrrolobenzodiazepines et conjugues de celles-ci
WO2012005982A2 (fr) 2010-07-06 2012-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Rapporteur pour une terminaison par la arn polymérase ii
EA026142B1 (ru) 2010-07-23 2017-03-31 Такеда Фармасьютикал Компани Лимитед Конденсированное гетероциклическое соединение и его применение
AU2011285919C1 (en) 2010-08-02 2015-09-17 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising VL domains
PL2611785T3 (pl) 2010-09-01 2014-10-31 Bayer Ip Gmbh Amidy kwasu N-(tetrazol-5-ilo)- i N-(triazol-5-ilo)arylokarboksylowego i ich zastosowanie jako środki chwastobójcze
US9238690B2 (en) 2010-10-29 2016-01-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
US20120302505A1 (en) 2011-04-21 2012-11-29 Fetzer Oliver S Cyclodextrin-based polymers for therapeutic delivery
MX371526B (es) 2011-05-27 2020-01-31 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
WO2013053872A1 (fr) 2011-10-14 2013-04-18 Spirogen Sàrl Procédé de synthèse et intermédiaires pouvant servir à préparer des pyrrolobenzodiazépines
CA2850103C (fr) 2011-10-14 2019-09-10 Spirogen Sarl Pyrrolobenzodiazepines
EP3309162A1 (fr) 2011-10-14 2018-04-18 Seattle Genetics, Inc. Conjugues cibles des pyrrolobenzodiazepines
ES2945932T3 (es) 2011-10-14 2023-07-10 Seagen Inc Pirrolobenzodiazepinas y conjugados dirigidos
WO2013068874A1 (fr) 2011-11-11 2013-05-16 Pfizer Inc. Conjugués anticorps-médicament
EP2780009A4 (fr) 2011-11-17 2015-05-06 Univ Colorado Regents Procédés et compositions pour une administration améliorée de médicament à l' il et formulations d'administration prolongée
EP2793585A4 (fr) 2011-12-05 2015-12-09 Igenica Biotherapeutics Inc Conjugués anticorps-médicament et composés, compositions et méthodes connexes
GB201122325D0 (en) 2011-12-23 2012-02-01 Cytoguide As Novel formulations
EP2809686A4 (fr) * 2012-01-31 2015-11-25 Cerulean Pharma Inc Polymères à base de cyclodextrine pour administration thérapeutique
CN114133454A (zh) 2012-03-14 2022-03-04 瑞泽恩制药公司 多特异性抗原结合分子及其用途
CN104619350A (zh) 2012-06-14 2015-05-13 Ambrx公司 结合到核受体配体多肽的抗psma抗体
SG11201501920PA (en) 2012-10-11 2015-04-29 Ascendis Pharma As Diagnosis, prevention and treatment of diseases of the joint
EA201590622A1 (ru) 2012-10-16 2015-10-30 Эндосайт, Инк. Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
HUE038285T2 (hu) 2012-10-23 2018-10-29 Synaffix Bv Módosított antitest, antitest-konjugátum és eljárás ezek elõállítására
US9376420B2 (en) 2012-10-25 2016-06-28 Yuhan Corporation 4,5-dihydro-1H-pyrazole derivative or salts thereof, and pharmaceutical composition comprising same
CN103044523B (zh) * 2012-12-13 2014-05-21 济南向惠医药技术有限公司 地塞米松-rgd多肽缀合物，其制备方法及应用
JP6382221B2 (ja) 2012-12-24 2018-08-29 アッヴィ・インコーポレイテッド プロラクチン受容体結合タンパク質およびそれらの使用
MX2015011367A (es) 2013-03-13 2015-12-16 Seattle Genetics Inc Ciclodextrina y formulaciones de conjugados anticuerpo-farmaco.
US20160082119A1 (en) 2013-04-22 2016-03-24 Avelas Biosciences, Inc. Selective drug delivery compositions and methods of use
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
WO2014197854A1 (fr) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Nouveaux lieurs pour conjugués anticorps-médicament et composés connexes, compositions, et procédés d'utilisation
JP6744212B2 (ja) * 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
US20160158369A1 (en) 2013-07-10 2016-06-09 Seikagaku Corporation Pharmaceutical composition for respiratory administration
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
HUE051389T2 (hu) 2013-10-15 2021-03-01 Seagen Inc Pegilezett gyógyszer-linkerek ligandum-gyógyszer konjugátum javított farmakokinetikájához
CN103694375B (zh) 2013-12-13 2016-10-05 北京大学 一种三萜-环糊精共价化合物及其制备方法和用途
WO2015110609A1 (fr) 2014-01-24 2015-07-30 Centre National De La Recherche Scientifique Composés disponibles par voie orale, procédé pour leur préparation et leurs utilisations comme médicaments anti-adhérences pour le traitement de maladies intestinales inflammatoires induites par e. coli, telles que la maladie de crohn
JP2017511376A (ja) * 2014-03-21 2017-04-20 アッヴィ・インコーポレイテッド 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート
EP3125943A4 (fr) 2014-04-04 2017-12-06 Merck Sharp & Dohme Corp. Lieurs à base de phosphates pour introduction intracellulaire de conjugués médicamenteux
KR102445502B1 (ko) 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
WO2015189478A1 (fr) 2014-06-13 2015-12-17 Glykos Finland Oy Conjugués charge utile-polymère-protéine
KR20170086542A (ko) 2014-12-03 2017-07-26 제넨테크, 인크. 항-스타필로코쿠스 아우레우스 항체 리파마이신 콘주게이트 및 그것의 용도
CN107206102A (zh) 2014-12-03 2017-09-26 豪夫迈·罗氏有限公司 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
BR112017012342A2 (pt) 2014-12-09 2018-02-27 Abbvie Inc compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos
RU2020123953A (ru) 2014-12-09 2020-09-18 Эббви Инк. Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и конъюгаты антитело-лекарственное средство, включающие их
US10233210B2 (en) 2015-01-30 2019-03-19 Coral Drugs Pvt. Ltd. Process for preparation of glucocorticoid steroids
JP2018507844A (ja) 2015-02-06 2018-03-22 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 抗体薬物コンジュゲート
WO2016168769A1 (fr) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Commutateurs de lymphocytes t récepteurs chimériques pour her2
WO2017007796A1 (fr) 2015-07-06 2017-01-12 Regeneron Pharmaceuticals, Inc. Molécules multispécifiques de liaison à l'antigène et leurs utilisations
WO2017006279A1 (fr) 2015-07-08 2017-01-12 Aten Porus Lifesciences Compositions et complexes de cyclodextrine-polymère et leurs procédés de préparation et d'utilisation
EP3346997A4 (fr) 2015-09-10 2019-05-15 Shasqi, Inc. Compositions bio-orthogonales
US11510993B2 (en) 2015-10-06 2022-11-29 Merck Sharp & Dohme Llc Antibody drug conjugate for anti-inflammatory applications
US10869929B2 (en) 2016-01-29 2020-12-22 Merck Sharp & Dohme Corp. Phosphonate linkers and their use to facilitate cellular retention of compounds
US11786603B2 (en) 2016-02-26 2023-10-17 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
US11844839B2 (en) 2016-03-25 2023-12-19 Seagen Inc. Process for the preparation of pegylated drug-linkers and intermediates thereof
WO2017189996A1 (fr) * 2016-04-29 2017-11-02 Brandeis University Conjugués d'acides aminés et de peptides-stéroïdes et leur utilisation
GB201608936D0 (en) 2016-05-20 2016-07-06 Polytherics Ltd Novel conjugates and novel conjugating reagents
BR112018074922B1 (pt) 2016-06-02 2022-10-25 Abbvie Inc Compostos agonistas de receptores de glucocorticoides, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
MX2018015272A (es) 2016-06-08 2019-08-12 Abbvie Inc Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
WO2018058001A1 (fr) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anticorps anti-steap2, conjugués anticorps-médicament, et molécules bispécifiques de liaison à l'antigène qui se lient à steap2 et cd3, et leurs utilisations
MX2019005330A (es) * 2016-11-08 2019-09-11 Regeneron Pharma Esteroides y conjugados de proteinas de los mismos.
EP3625209A1 (fr) 2017-05-18 2020-03-25 Regeneron Pharmaceuticals, Inc. Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
MX2019013690A (es) 2017-05-18 2020-01-27 Regeneron Pharma Conjugados de farmaco-proteina con ciclodextrina.
CN118652192A (zh) * 2017-05-24 2024-09-17 德克萨斯州大学系统董事会 用于抗体药物缀合物的接头
WO2019034176A1 (fr) 2017-08-18 2019-02-21 四川百利药业有限责任公司 Conjugué de camptothécine-anticorps
CN108853514B (zh) 2017-08-18 2022-07-22 四川百利药业有限责任公司 具有两种不同药物的抗体药物偶联物
KR20200085807A (ko) 2017-11-07 2020-07-15 리제너론 파마슈티칼스 인코포레이티드 항체 약물 접합제용 친수성 링커
MA54673A1 (fr) 2018-01-08 2022-08-31 Regeneron Pharma Stéroïdes et leurs conjugués-anticorps
CA3098453A1 (fr) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anticorps anti-msr1 et leurs procedes d'utilisation
CN113226470A (zh) 2018-12-21 2021-08-06 瑞泽恩制药公司 利福霉素类似物及其抗体-药物缀合物
KR20210114008A (ko) 2019-01-08 2021-09-17 리제너론 파마슈티칼스 인코포레이티드 흔적이 없는 링커 및 이의 단백질-접합체
US20230119539A1 (en) * 2019-01-08 2023-04-20 Regeneron Pharmaceuticals, Inc. Traceless linkers and protein-conjugates thereof

Also Published As

Publication number Publication date
JP7366028B2 (ja) 2023-10-20
JP2024009905A (ja) 2024-01-23
SG11202006510XA (en) 2020-08-28
CN118955604A (zh) 2024-11-15
CN112004557A (zh) 2020-11-27
CN112004557B (zh) 2024-07-30
CL2020001813A1 (es) 2020-10-23
WO2019136487A3 (fr) 2019-09-12
EA202091672A1 (ru) 2021-02-01
AU2019205542A1 (en) 2020-07-16
US12070506B2 (en) 2024-08-27
BR112020013492A2 (pt) 2020-12-08
EP3737420A2 (fr) 2020-11-18
WO2019136487A2 (fr) 2019-07-11
US20190209702A1 (en) 2019-07-11
KR20200108002A (ko) 2020-09-16
CO2020009644A2 (es) 2020-10-30
MX2020006994A (es) 2020-11-06
JP2021509908A (ja) 2021-04-08
IL275757A (en) 2020-08-31
US20240342299A1 (en) 2024-10-17
MA50259A1 (fr) 2021-07-29
CA3086926A1 (fr) 2019-07-11
PH12020551044A1 (en) 2021-04-26

Similar Documents

Publication Publication Date Title
MA54673A1 (fr) Stéroïdes et leurs conjugués-anticorps
WO2019010222A3 (fr) Polynucléotides codant pour des molécules de fusion immunostimulantes et leurs utilisations
PH12021500030A1 (en) Il-2 conjugates and methods of use thereof
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
SA520411202B1 (ar) مترافقات سيتوكين لعلاج أمراض المناعة الذاتية
PH12019500365A1 (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
MA41013B1 (fr) Compositions comprenant des souches bactériennes
BR112021016056A2 (pt) Anticorpos de claudina 6 e usos dos mesmos
MA38859B1 (fr) Anticorps anti-c5 présentant une pharmacocinétique améliorée
MA47392B1 (fr) Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
MA40662B1 (fr) Anticorps contre tigit
PH12021550611A1 (en) Interleukin 10 Conjugates and Uses Thereof
BR112022001575A2 (pt) Formulações de anticorpos anti-pvrig e usos dos mesmos
MX2022012991A (es) Anticuerpos anti-vista humanos y uso de estos.
SA520412283B1 (ar) Cd22 أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ
MA49373B1 (fr) Compositions comprenant des souches bactériennes
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
MA45752B2 (fr) Stéroïdes et leurs conjugués protéiques
MX2022005251A (es) Conjugados de interleuquina 10 y sus usos.
EA202193121A1 (ru) Лечение рака
MA53186B2 (fr) Anticorps monoclonal qui se lie spécifiquement à cd20
MA51297B1 (fr) Quinazolinones en tant qu'inhibiteurs de parp14
MA53413B1 (fr) Composés antibiotiques, leurs procédés de fabrication, compositions pharmaceutiques les contenant et leurs utilisations
FR3102175B1 (fr) Nouveaux anticorps monoclonaux therapeutiques humains et leurs utilisations
EA201992647A1 (ru) Композиции, содержащие бактериальные штаммы